Siplizumab
- Generic Name
- Siplizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 288392-69-8
- Unique Ingredient Identifier
- KUW1QG1ZM3
- Indication
Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of SIPLIZUMAB in AILD and LT Patients
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Elizabeth C. Verna
- Target Recruit Count
- 8
- Registration Number
- NCT06455280
- Locations
- 🇺🇸
Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York, United States
A Study to Demonstrate the Safety and Efficacy of Siplizumab in the Treatment of Hidradenitis Suppurativa
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 12
- Registration Number
- NCT06326476
Siplizumab for Sickle Cell Disease Transplant
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Markus Mapara
- Target Recruit Count
- 18
- Registration Number
- NCT06078696
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Delayed Tolerance Through Mixed Chimerism
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05900401
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Siplizumab in T1DM
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-08-02
- Target Recruit Count
- 120
- Registration Number
- NCT05574335
- Locations
- 🇺🇸
Stanford School of Medicine: Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Stanford, California, United States
🇺🇸Emory University School of Medicine: Emory & Children's Pediatric Research Center, Division of Endocrinology & Diabetes, Atlanta, Georgia, United States
🇺🇸The University of Chicago: Duchossois Center for Academic Medicine-Hyde Park, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.